Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(cabergoline)
1,750 results
  • Current Status of Diagnosis and Management of Functioning Pituitary Tumors: Part II. [Review]
    Neurol India. 2020 May-Jun; 68(Supplement):S20-S27.Gada JV, Sanamandra P, … Bhagwat NM
  • Functioning pituitary tumors contribute to significant morbidity and mortality. Proper diagnostic approach and management is essential for optimal outcomes. Prolactinomas, the commonest of these, are the only tumors which can be managed medically. Acromegaly, apart from acral enlargement, can have multiple comorbidities like diabetes, hypertension, and obstructive sleep apnea. The primary treatme…
  • The prevalence of silent acromegaly in prolactinomas is very low. [Journal Article]
    J Endocrinol Invest. 2020 Jun 27 [Online ahead of print]Bona C, Prencipe N, … Grottoli S
  • CONCLUSIONS: The prevalence of silent acromegaly in prolactinomas (0.7%) is lower than previously reported and OGTT is helpful to recognize silent acromegaly. We suggest that the somatotroph axis should be evaluated at diagnosis in all cases and not systematically during follow-up.
  • The KBTBD6/7-DRD2 axis regulates pituitary adenoma sensitivity to dopamine agonist treatment. [Journal Article]
    Acta Neuropathol. 2020 Jun 22 [Online ahead of print]Liu YT, Liu F, … Wu ZB
  • Pituitary adenoma (PA) is one of the most common intracranial tumors, and approximately 40% of all PAs are prolactinomas. Dopamine agonists (DAs), such as cabergoline (CAB), have been successfully used in the treatment of prolactinomas. The expression of dopamine type 2 receptor (DRD2) determines the therapeutic effect of DAs, but the molecular mechanisms of DRD2 regulation are not fully understo…
  • Dopamine modulates dynamic decision-making during foraging. [Journal Article]
    J Neurosci. 2020 May 26 [Online ahead of print]Le Heron C, Kolling N, … Apps MAJ
  • The mesolimbic dopaminergic system exerts a crucial influence on incentive processing. However, the contribution of dopamine in dynamic, ecological situations where reward rates vary, and decisions evolve over time, remains unclear. In such circumstances, current (foreground) reward accrual needs to be compared continuously with potential rewards that could be obtained by travelling elsewhere (ba…
  • Octreotide-Resistant Acromegaly: Challenges and Solutions. [Review]
    Ther Clin Risk Manag. 2020; 16:379-391.Corica G, Ceraudo M, … Gatto F
  • Acromegaly is a rare and severe disease caused by an increased and autonomous secretion of growth hormone (GH), thus resulting in high circulating levels of insulin-like growth factor 1 (IGF-1). Comorbidities and mortality rate are closely related to the disease duration. However, in most cases achieving biochemical control means reducing or even normalizing mortality and restoring normal life ex…
  • Endocrinology in the time of COVID-19: Management of pituitary tumours. [Journal Article]
    Eur J Endocrinol. 2020 Jul; 183(1):G17-G23.Fleseriu M, Dekkers OM, Karavitaki N
  • Patients with pituitary tumours, ensuing hormonal abnormalities and mass effects are usually followed in multidisciplinary pituitary clinics and can represent a management challenge even during the times of non-pandemic. The COVID-19 pandemic has put on hold routine medical care for hundreds of millions of patients around the globe, while many pituitary patients' evaluations cannot be delayed for…
  • OATP1A2 and OATP2B1 Are Interacting with Dopamine-Receptor Agonists and Antagonists. [Journal Article]
    Mol Pharm. 2020 Jun 01; 17(6):1987-1995.Schäfer AM, Meyer Zu Schwabedissen HE, … Grube M
  • Interaction with the dopaminergic system in the central nervous system is either therapeutically intended or it is a side effect. In both cases, dopamine-receptor agonists (DRA) like the ergoline derivative bromocriptine and dopamine-receptor antagonists (DRAn) like metoclopramide have to cross the blood-brain barrier (BBB). The organic anion transporting polypeptides (OATP) 1A2 and 2B1 are cellu…
  • Ectopic Prolactin Secretion From a Uterine Leiomyoma. [Case Reports]
    J Endocr Soc. 2020 Apr 01; 4(4):bvaa035.Sachdev S, Reyes MC, Snyder PJ
  • Ectopic hormone production is well recognized, but ectopic production of prolactin has been reported infrequently. We report here the case of a 47-year-old woman who had hyperprolactinemia (213-224 ng/mL) causing galactorrhea and hypogonadism. Cabergoline treatment, 1.0 mg twice a week, did not lower the prolactin level at all, but excision of a large uterine leiomyoma corrected the hyperprolacti…
  • Monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia. [Journal Article]
    Ann Endocrinol (Paris). 2020 Feb 28 [Online ahead of print]Stiles CE, Steeds RP, Drake WM
  • The surveillance strategy for patients taking low dose cabergoline for hyperprolactinaemia is controversial. As more evidence has emerged that the risks of cardiac valvulopathy in this population of patients are low, fewer and fewer endocrinologists adhere strictly to the original medicines and healthcare products agency MHRA guidance of "at least" annual echocardiography. Strict adherence to thi…
  • Restoration of fertility in a woman with giant prolactinoma in response to cabergoline treatment. [Journal Article]
    Endocrinol Diabetes Metab Case Rep. 2019 Sep 06; 2019Astaf'eva LI, Sidneva YG, … Agadzhanian SA
  • A 32-year-old woman presented with primary amenorrhoea, prolactin (PRL) level of 154 150 mIU/L and was diagnosed with a giant pituitary adenoma measuring maximum 6.2 cm. Cabergoline (CAB) treatment at a dose of 0.5 mg/week was prescribed to the patient. The treatment decreased the tumour size after 3 months (MRI scans of the brain) and brought back to normal the level of the PRL (345 mIU/L) after…
  • AN UNEXPECTED COMBINATION OF PROLACTINOMA AND SEPTO-OPTIC DYSPLASIA. [Case Reports]
    AACE Clin Case Rep. 2019 Sep-Oct; 5(5):e282-e286.Rahhal MN, Kassem LS
  • CONCLUSIONS: We conclude that a diagnosis of SOD should not exclude the possibility of a pituitary adenoma in the appropriate clinical context, and that the pattern of hormonal deficits in such a combination may be uncharacteristic of the deficits expected with pituitary adenoma alone.
New Search Next